<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta name="robots" content="noindex, nofollow">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Neurology Summary – James Saint</title>
    <meta name="description" content="Neurology Summary" />
    <meta property="og:title" content="Neurology Summary – James Saint" />
    <meta property="og:description" content="Chronological overview of neurological investigations" />
    <meta property="og:image" content="https://jamessaint.github.io/assets/seed-of-life-gold.jpg" />
    <meta property="og:type" content="website" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:title" content="Neurology Summary – James Saint" />
    <meta name="twitter:description" content="Chronological overview of neurological investigations." />
    <meta name="twitter:image" content="https://jamessaint.github.io/assets/seed-of-life-gold.jpg" />
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" />
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
    <link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet">
<link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet">
<link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet">
<link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet">
<link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet">
</head>

<body>
    <main class="content">
        <nav aria-label="breadcrumb">
            <ol class="breadcrumb">
                <li class="breadcrumb-item"><a href="/medical/">Medical Home</a></li>
                <li class="breadcrumb-item"><a href="/medical/neurological/">Neurological</a></li>
                <li class="breadcrumb-item active" aria-current="page">Neurology Summary</li>
            </ol>
        </nav>
        <header>
            <h1>Neurology Summary</h1>
        </header>
        <section id="appointments">
            <h2>Appointments Attended (Chronological)</h2>
            <div class="table-wrap">
                <table>
                    <thead>
                        <tr>
                            <th>Date</th>
                            <th>Appointment</th>
                            <th>Location</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>24 April 2025</td>
                            <td>Private GP Referral</td>
                            <td>Doctor Care Anywhere</td>
                        </tr>
                        <tr>
                            <td>15 May 2025</td>
                            <td>Initial Consultation Dr. Omar Malik</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                        <tr>
                            <td>15 May 2025</td>
                            <td>Blood Tests (immune & metabolic panels)</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                            <td>15 June 2025</td>
                            <td>Evoked Potentials</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                            <td>23 July 2025</td>
                            <td>1.5 T MRI Brain & Cervical Spine</td>
                            <td>Mount Alvernia Imaging</td>
                        </tr>
                        <tr>
                            <td>31 July 2025</td>
                            <td>CT Angiogram (extracranial carotid & vertebral circulation)</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                            <td>31 July 2025</td>
                            <td>Bubble Echocardiogram</td>
                            <td>Surrey Cardiovascular Clinic</td>
                        </tr>
                        <tr>
                            <td>31 July 2025</td>
                            <td>Lumbar Puncture (CSF examination)</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                            <td>14 August 2025</td>
                            <td>Follow-up Review with Dr Malik</td>
                            <td>Mount Alvernia Hospital</td>
                        </tr>
                        <tr>
                            <td>17 September 2025</td>
                            <td>3 T MRI Brain & Cervical Spine</td>
                            <td>Charing Cross Hospital</td>
                        </tr>
                        <tr>
                            <td>7 October 2025</td>
                            <td>Follow-up Review with Dr Malik</td>
                            <td>Telephone Consultation</td>
                        </tr>
                        <tr>
                            <td>[Pending] 5 November 2025</td>
                            <td>Dr Malik Review with MDT</td>
                            <td>Cromwell Hospital</td>
                        </tr>
                        <tr>
                            <td>[Pending] 6 November 2025</td>
                            <td>Follow-up Review with Dr Malik</td>
                            <td>TBC</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </section>
        <section id="diagnostic-hypotheses" class="section card-like diagnostic-section">
            <h2>Diagnostic Hypotheses</h2>
            <div class="diagnostic-block previous">
                <h3>Initial Hypothesis (July 2025)</h3>
                <p>
                    Early imaging and clinical correlation suggested a <strong>right cerebellar infarct of uncertain cause</strong>.
                    <strong>CT angiogram</strong> of the extracranial carotid/vertebral circulation and a <strong>bubble echocardiogram</strong>
                    did <strong>not identify an embolic source</strong>. Lumbar puncture showed <strong>no oligoclonal bands</strong> or CSF inflammatory markers.
                </p>
                <p>
                    A <strong>subtle C5/6 cervical cord signal change</strong> on the 1.5&nbsp;T study was interpreted as possible residual
                    from prior <strong>myelitis</strong>, pending further correlation. Subsequent opinions queried whether this represented
                    true cord pathology or artefact/resolving change.
                </p>
            </div>
            <div class="diagnostic-block current">
                <h3>Current Working Hypothesis (September–November 2025)</h3>
                <p>
                    On 3&nbsp;T review there is <strong>no demonstrable spinal cord signal change</strong>, making an active myelitis explanation
                    <strong>less tenable</strong>. The evolving picture favors a <strong>small, radiologically indiscernible right-sided brainstem stroke</strong> in the
                    same arterial territory as the cerebellar infarct as the most plausible unifying explanation for the persistent
                    <strong>left-sided sensory symptoms and occipital pain</strong>.
                </p>
                <p>
                    <em>Vascular work-up to date remains negative for an embolic source.</em> Given the <strong>acute onset after the second AstraZeneca COVID-19 vaccine</strong>
                    and the imaging correlation, the consultant considers a <strong>vaccine-related thromboembolic mechanism more likely</strong> than alternative explanations
                    such as smoking history.
                </p>
                <p>
                    <strong>Central post-stroke pain</strong> is considered a leading component of the symptom profile.
                </p>
                <p class="note">
                    <strong>MDT review scheduled:</strong> Cromwell Hospital, <strong>5 November 2025</strong>, to correlate brainstem–cerebellar findings and agree further imaging or management.
                </p>
            </div>
            <div class="diagnostic-block next-steps">
                <h3>Planned / Ongoing Actions</h3>
                <ul>
                    <li><strong>MDT review</strong> of brainstem and cerebellar findings on 5 November 2025, with cross-sequence correlation and prior study comparison.</li>
                    <li>Consider <strong>targeted brainstem MRI protocol</strong> if ambiguity persists after MDT discussion.</li>
                    <li><strong>Trial of Carbamazepine (Tegretol)</strong> initiated: 100&nbsp;mg once daily for 2&nbsp;weeks, then 100&nbsp;mg twice daily, to assess neuropathic modulation prior to MDT feedback.</li>
                    <li>Symptom-led management pathway acknowledging probable <strong>central post-stroke pain</strong>.</li>
                </ul>
                <p class="meta">
                    Prior intolerance to duloxetine, pregabalin and gabapentin noted; carbamazepine chosen as an alternative class for neuropathic modulation.
                </p>
            </div>
        </section>
<section id="symptoms">
  <h2>Symptom Overview</h2>
  <p>Summary of symptom patterns and functional impact below.</p>

  <div class="table-wrap">
    <table>
      <thead>
        <tr>
          <th>Category</th>
          <th>Description</th>
          <th>Functional Impact</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td><strong>Throat & Facial Tension</strong></td>
          <td>Left-sided throat and facial tightness, intermittent jaw and ear pressure, voice fatigue, and a persistent phlegm sensation (possible vagus nerve involvement).</td>
          <td>Voice tires with extended conversation or reading aloud; meals and hydration are slower on high-symptom days; public speaking or long calls increase strain and recovery time.</td>
        </tr>

        <tr>
          <td><strong>Leg, Foot & Groin</strong></td>
          <td>Left calf heaviness, foot instability on uneven ground, intermittent tingling or numbness, groin and testicular pain, and pelvic floor tension (possible L4–S1 and pudendal/genitofemoral nerve involvement).</td>
          <td>Walking distance and pace reduced during flares; balance and single-leg stance feel less secure on the left; sitting tolerance affected by pelvic discomfort; sexual comfort and function fluctuate.</td>
        </tr>

        <tr>
          <td><strong>Upper Limb & Hand</strong></td>
          <td>Left dorsal hand and wrist tingling with intermittent burning and pain that localises to the middle finger. Occasional wrist discomfort and reduced dexterity during flares.</td>
          <td>Typing, gripping, utensil use, and other fine motor tasks are slower and fatigue quickly; handwriting and precision decrease during symptom peaks.</td>
        </tr>

        <tr>
          <td><strong>Occipital & Scalp</strong></td>
          <td>Patchy hair loss and regrowth within the occipital and posterior parietal scalp regions, correlating with greater, lesser, and third occipital nerve pathways (C2–C3). Features of occipital neuralgia with scalp allodynia. Full mapping and images are available in
            <a href="https://jamessaint.github.io/medical/neurological/Occipital_Scalp_Changes_Nerve_Path_Mapping.html" target="_blank" rel="noopener">Occipital Scalp Changes - Nerve Path Mapping</a>.
          </td>
          <td>Fluctuating scalp sensitivity and pain may coincide with hair density changes; prolonged pressure on the back of the head or temperature shifts can increase discomfort; tension or paresthesia may extend into the neck or upper trapezius.</td>
        </tr>

        <tr>
          <td><strong>Sensory & Pain</strong></td>
          <td>Occipital area pain and pressure, intermittent facial and scalp paresthesia on the left, and occasional light-touch or temperature asymmetry. Central neuropathic pain overlay with peripheral triggers.</td>
          <td>Sustained screen time, bright lighting, or head movements increase occipital pain; sleep can be disrupted, reducing next-day stamina; requires pacing and heat-based relief.</td>
        </tr>

        <tr>
          <td><strong>Trigeminal-Occipital Convergence</strong></td>
          <td>Persistent left-sided eyebrow-to-scalp pain radiating from the occipital region across the temple and into the cheek, with facial fullness and tingling. Distribution aligns with ophthalmic (V1) and maxillary (V2) trigeminal branches with possible occipital nerve interplay.</td>
          <td>Discomfort behind the eye and across the brow; bending forward can accentuate facial heaviness; contributes to sensory overload, light sensitivity, and fatigue on high-symptom days.</td>
        </tr>

        <tr>
          <td><strong>Visual & Vestibular</strong></td>
          <td>Intermittent disturbance in the left visual field, eye strain, and dizziness with rapid head turns. Motion and visually busy environments increase symptoms.</td>
          <td>Reading and multitasking are slower; prefers larger fonts and reduced motion; needs regular breaks and steady visual anchors for balance.</td>
        </tr>

        <tr>
          <td><strong>Cognitive & Energy</strong></td>
          <td>Mental fatigue, word-finding lapses, slower processing under cognitive load, and reduced stress tolerance, especially during flares.</td>
          <td>Complex tasks benefit from chunking and written checklists; requires recovery time after demanding activity; decision quality drops when multitasking or overtired.</td>
        </tr>

        <tr>
          <td><strong>Autonomic & General</strong></td>
          <td>Fatigue disproportionate to effort, heart-in-throat sensations, and temperature intolerance during flares. Heightened reactivity to stress.</td>
          <td>Benefits from calm start-up to demanding interactions, breathing resets, gentle pacing, and consistent daily rhythm; overstimulation prolongs recovery.</td>
        </tr>
      </tbody>
    </table>
  </div>
</section>

        <section id="mast-cell-activation-differential" class="section card-like">
            <h2>Mast Cell Activation Differential & Further Investigations Requested</h2>
            <p>
                Following comprehensive autoimmune, infectious, and immunoglobulin screening, all of which returned negative or within reference range,
                a <strong>mast cell activation–mediated process</strong> remains a plausible untested contributor to the multisystem symptoms observed
                (neuropathic pain, pruritus, flushing, and autonomic instability).
            </p>
            <p>
                Given the pattern of <strong>allergic-type reactions to multiple medications</strong> and autonomic dysregulation despite normal ANA, ENA, ANCA,
                complement, and immunoglobulin profiles, it is reasonable to evaluate for <strong>Mast Cell Activation Syndrome (MCAS)</strong> as part of the ongoing
                differential.
            </p>
            <h3>Recommended Investigations</h3>
            <table>
                <thead>
                    <tr>
                        <th>Test</th>
                        <th>Purpose</th>
                        <th>Specimen</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Serum Tryptase</strong></td>
                        <td>Baseline and repeat during a flare to detect mast cell mediator release.</td>
                        <td>Blood (serum)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary N-Methylhistamine</strong></td>
                        <td>Measures histamine metabolite to assess systemic mast-cell activity.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Prostaglandin D₂ & 11-β-PGF₂α</strong></td>
                        <td>Detects mast-cell–derived prostanoid release contributing to inflammation or pain.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Leukotriene E₄</strong></td>
                        <td>Assesses eicosanoid pathway activation in hypersensitivity or MCAS.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>Chromogranin A</strong></td>
                        <td>Optional marker for neuroendocrine activation overlap.</td>
                        <td>Blood (serum)</td>
                    </tr>
                </tbody>
            </table>
            <h3>Clinical Rationale</h3>
            <p>
                Mast cell activation may bridge immunological and neurological mechanisms, aligning with the presentation of
                <strong>fluctuating neuropathic pain, pruritus, autonomic instability, drug hypersensitivity, and inflammatory reactivity</strong>.
                These investigations would clarify whether mast-cell mediator release underlies, amplifies, or mimics autoimmune or neuro-inflammatory processes.
            </p>
            <h3>Request Summary</h3>
            <p>
                Kindly consider inclusion of these MCAS-specific mediator studies within the next diagnostic round or MDT review,
                to provide a more complete immunoneuro-inflammatory profile and identify any treatable mast-cell–driven component.
            </p>
            <h3>Referenced Blood Test Reports</h3>
            <ul>
                <li><a href="blood_tests/20-05-2025-Scanned-Letter-40157630_redacted.pdf" target="_blank">20 May 2025 – Blood Sciences (ANA, ENA, Immunoglobulins, Lyme, Complement)</a></li>
                <li><a href="blood_tests/21-05-2025-Scanned-Letter-40157721_redacted.pdf" target="_blank">21 May 2025 – Autoimmune & HLA-B27 Screening (Negative)</a></li>
                <li><a href="blood_tests/02-08-2025-Scanned-Letter-40162215_redacted.pdf" target="_blank">02 Aug 2025 – CSF Analysis & Pending Immunology (Preliminary)</a></li>
                <li><a href="blood_tests/04-08-2025-Scanned-Letter-40162434_redacted.pdf" target="_blank">04 Aug 2025 – CSF Microbiology (No Growth, Normal Glucose & Protein)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162651_redacted.pdf" target="_blank">08 Aug 2025 – Serum ACE, MOG, and Aquaporin-4 Antibody Results (All Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162652_redacted.pdf" target="_blank">08 Aug 2025 – CSF Aquaporin-4 Antibodies (Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162684_redacted.pdf" target="_blank">08 Aug 2025 – Patient Summary Reference Page (Administrative)</a></li>
            </ul>
            <div class="note">
                <p><strong>Next step:</strong> Discuss with Dr Omar Malik or the Cromwell MDT whether these mast-cell mediator assays can be incorporated into upcoming laboratory orders or future multidisciplinary correlation review.</p>
            </div>
        </section>
        <section class="section card-like">
            <h2>Neurologist Letters</h2>
            <ul>
                <li><a href="letters/gp-referral-2442025-redacted.pdf" target="_blank">24 April 2025 – Private Referral (Doctor Care Anywhere)</a></li>
                <li><a href="letters/18-05-2025-gp-letter-001575064_redacted.pdf" target="_blank">18 May 2025 – Initial Neurology Assessment</a></li>
                <li><a href="letters/10-07-2025-gp-letter-001614424_redacted.pdf" target="_blank">10 July 2025 – Follow-up (MRI results, CT &amp; Bubble Echo Plan)</a></li>
                <li><a href="letters/03-08-2025-gp-letter-001622984_redacted.pdf" target="_blank">3 August 2025 – Lumbar Puncture Outcome Note</a></li>
                <li><a href="letters/17-08-2025-g-p--letter-001633154_redacted.pdf" target="_blank">17 August 2025 – Post-CSF Review &amp; Cervical Spine Imaging Plan</a></li>
                <li><a href="letters/08-10-2025-g-p-letter-001666084-redacted.pdf" target="_blank">8 October 2025 – Brainstem Stroke Hypothesis &amp; Carbamazepine Trial</a></li>
            </ul>
            <p class="note">All correspondence above has been redacted for privacy.</p>
        </section>
    </main>
</body>

</html>